Live Breaking News & Updates on Ronac Mamtani

Stay updated with breaking news from Ronac mamtani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches to Treatment Selection in Prostate Cancer

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach. ....

Fox Chase Cancer Center , United States , University Of Pennsylvania , Pooja Ghatalia , Jasone Shpilsky , Vivekk Narayan , Kevin Kayvan Zarrabi , Ronac Mamtani , Samuel Takvorian , Sidney Kimmel Cancer Center At Jefferson Health , Hospital Of The University Pennsylvania , Penn Medicine , Sidney Kimmel Cancer Center , Prostate Cancer ,

Maintenance Avelumab Uptake Modest in Advanced Urothelial Carcinoma

The approval and uptake of maintenance avelumab for urothelial carcinoma is associated with upstream firstline treatment selection. ....

University Of Pennsylvania , United States , Ronac Mamtani , Flatiron Health ,

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

United States , Vivek Nimgaonkar , Ronac Mamtani , Penn Center , University Of Pennsylvania , Drug Administration , Biopsy Laboratory , Perelman School Of Medicine , American Cancer Society , Perelman School , Erica Carpenter , Liquid Biopsy , Fibroblast Growth Factor Receptors ,

UPenn Researchers Find Low Uptake of Janssen's Balversa in Eligible Bladder Cancer Patients

While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested. ....

Vivek Nimgaonkar , Janssen Balversa , Qiagen Therascreen , Ronac Mamtani , Penn Center , Ohio State University Comprehensive Cancer Center James , Tumor Material Laboratory , Drug Administration , University Of Pennsylvania , Flatiron Health , Precision Medicine , Erica Carpenter , Circulating Tumor Material Laboratory ,

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania. ....

United States , Vivek Nimgaonkar , Ronac Mamtani , Emily Henderson , Penn Center , University Of Pennsylvania , Drug Administration , Biopsy Laboratory , Perelman School Of Medicine , American Cancer Society , Perelman School , Erica Carpenter , Liquid Biopsy , Fibroblast Growth Factor Receptors , Bladder Cancer , Cancer Treatment , Clinical Trial , Precision Medicine ,